Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
Haematologica
.
2022 Jul 1;107(7):1726-1730.
doi: 10.3324/haematol.2021.280567.
Authors
Cathelijne Fokkema
1
,
Phillipe Moreau
2
,
Bronno Van der Holt
3
,
Jérôme Lambert
4
,
Mark Van Duin
1
,
Ruth Wester
1
,
Joost L M Jongen
5
,
Pieter A Van Doorn
5
,
Sophie Godet
6
,
Kon Siong Jie
7
,
Olivier Fitoussi
8
,
Michel Delforge
9
,
Awa Keita-Manta
10
,
Odile Luycx
11
,
Tom Cupedo
1
,
Niels W C J Van de Donk
12
,
Sonja Zweegman
12
,
Jessica T Vermeulen
13
,
Pieter Sonneveld
1
,
Annemiek Broijl
14
Affiliations
1
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam.
2
Hematology Department, University Hospital Hôtel-Dieu, Nantes.
3
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam.
4
Biostatistical Department, Hospital Saint Louis, Paris.
5
Department of Neurology, Erasmus MC, Rotterdam.
6
Department of Hematology, University Hospital of Reims and UFR Médicine, Reims.
7
Department of Hematology, Zuyderland MC, Sittard.
8
Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux.
9
Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
10
Premier Research, CRO, Paris.
11
Department of Hematology, Hospital Scorff Hospital Group Bretagne Sud, Lorient.
12
Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam.
13
Janssen Research and Development, LLC, Leiden.
14
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam. a.broyl@erasmusmc.nl.
PMID:
35295081
PMCID:
PMC9244836
DOI:
10.3324/haematol.2021.280567
No abstract available
Publication types
Clinical Trial, Phase III
MeSH terms
Aged
Bortezomib / therapeutic use
Female
Humans
Male
Middle Aged
Peripheral Nervous System Diseases* / diagnosis
Peripheral Nervous System Diseases* / etiology
Substances
Bortezomib